trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Generic and original brand-name Clopidogrel have different adverse effect profiles

the verdict
REFUTED
the evidence says no
Recorded sources
0 sources for · 3 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that generic and original brand-name Clopidogrel have different adverse effect profiles?

No. Multiple large-scale clinical studies and retrospective cohort analyses comparing generic and brand-name clopidogrel have found no significant differences in their adverse effect profiles, such as bleeding risks or major adverse events.

Verdict: REFUTED · 0 sources for, 3 against · Last checked

The analysis

The claim states that generic and original brand-name clopidogrel have different adverse effect profiles. Papers [4], [5], and [7] directly examine this specific comparison for clopidogrel and conclude that there are no significant differences in safety profiles or adverse events (such as bleeding) between the generic and brand-name formulations. Therefore, the evidence clearly refutes the claim.

Evidence against · 3
Clinical outcomes of a generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: a nationwide retrospective cohort study.
2026
A nationwide retrospective cohort study found that generic and brand-name clopidogrel showed similar safety profiles regarding major bleeding and other adverse events.
Get citation
CJ, C., CH, H., FC, H., CP, L., TJ, H., & PH, C. (2026). Clinical outcomes of a generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: a nationwide retrospective cohort study.. doi.org. https://doi.org/10.1186/s12883-026-04760-5

See more details
More against · 2
Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: A nationwide retrospective cohort study
2025
A large-scale retrospective study demonstrated that the incidence of major bleeding and other adverse events was comparable between generic and brand-name clopidogrel.
Get citation
C, C., C, H., F, H., C, L., T, H., & P, C. (2025). Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: A nationwide retrospective cohort study. doi.org. https://doi.org/10.21203/rs.3.rs-7667267/v1

Clinical Outcomes and Safety Profiles of Generic Versus Brand-Name Clopidogrel in Patients Following Coronary Artery Stent Placement.
2025
A study following coronary artery stent placement found no significant differences in bleeding risk or adverse outcomes between generic and brand-name clopidogrel.
Get citation
CY, C., FC, H., TJ, H., YC, T., CP, L., & PH, C. (2025). Clinical Outcomes and Safety Profiles of Generic Versus Brand-Name Clopidogrel in Patients Following Coronary Artery Stent Placement.. doi.org. https://doi.org/10.1111/cts.70143

Receipt History
first checked06 Aug 2026
judged → REFUTED · 006 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work